A Phase IIa Randomized Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Non-ischemic Heart Failure

Trial Profile

A Phase IIa Randomized Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Non-ischemic Heart Failure

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2016

At a glance

  • Drugs Ischemia-tolerant mesenchymal stem cells (Primary)
  • Indications Chronic heart failure
  • Focus Adverse reactions
  • Sponsors CardioCell; Stemedica Cell Technologies
  • Most Recent Events

    • 14 Jun 2016 Results from this trial will be presented at the European Society of Cardiology (ESC) 2016 at the "Hot Line" Late-Breaking Science Session, according to a CardioCell media release.
    • 19 Apr 2016 The company expects to present preliminary results later this year, according to a CardioCell LLC media release.
    • 19 Apr 2016 Status changed from recruiting to active, no longer recruiting, according to a CardioCell LLC media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top